Currently, several FDA approved tests have been developed for the non-invasive diagnosis and surveillance of BlCa, including NMP22, BTA-TRAK, UroVysion and ImmunoCyt/uCyt + tests. Here, NUMA1 is linked to bladder transitional cell carcinoma.